Nurix Therapeutics, Inc.

Nurix Therapeutics is a clinical-stage company advancing three internally discovered and wholly owned drug-candidates designed to treat patients with hematologic malignancies and solid tumors. Nurix’s pipeline comprises both Targeted Protein Degraders to eliminate disease causing proteins and E3 ligase inhibitors that target key control elements in immune regulation (Targeted Protein Elevation).